Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments

Khatchatourian, Lydie; Bourgeois, Amandine Le; Asseray, Nathalie; Biron, Charlotte; Lefèbvre, M.; Navas, Dominique; Grégoire, Matthieu; Gaborit, Benjamin; Raffi, F.; Boutoille, David

doi:10.1093/jac/dkx097

Cited by 15 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, when modifications in drug disposition in previous cases were observed in the immediate postoperative period, body adaptation and return to baseline levels were reported (11). In terms of tolerance, the global and hematological safety profile of prolonged tedizolid treatment appears good, as suggested in a previous study (12). These results support the oral use of tedizolid 200 mg once daily in obese patients after restrictive bariatric surgery (1,2), although the data should be confirmed in a study with more patients and in the more immediate postoperative period.…”

mentioning

confidence: 67%

Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery

Grégoire

Libois

Waast³

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

An obese woman was treated with oral tedizolid 200 mg once daily for pseudoarthrosis 10 years after Roux-en-Y bypass surgery. Total plasma peak concentration was 2.12 mg/liter 3 h after intake, and area under the concentration-time curve from 0 to 24 h (AUC) was 28.3 mg/liter · h. The AUC/MIC ratio for unbound concentrations and for sensitive and strains was ≥10.8, higher than the target ratio of 3. These results support the use of tedizolid without adjustment after bariatric surgery.

show abstract

mentioning

confidence: 67%

Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery

Grégoire

Libois

Waast³

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…M. abscessus is sensitive to linezolid in-vitro, however long-term use is problematic due to the hematological and neurological side effects [4]. A newly developed oxazolidinone antimicrobial, tedizolid, an intravenous once daily agent, has more effective in-vitro bacteriostatic activity against M. abscessus , with less hematological and neurological toxicity compared to linezolid [16], [17], [18].…”

Section: Discussionmentioning

confidence: 99%

Medical management of atraumatic Mycobacterium abscessus cutaneous infection: A case report

Tiong

Nack

Tai

et al. 2019

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

Treatment for cutaneous infection from Mycobacterium abscessus is fraught with poorly established evidence. Given its antibiotic multi-resistance, surgical intervention is often recommended. We report a case of cutaneous M. abscessus infection that was successfully managed with medical therapy alone. A 55-year-old immunocompetent woman from the Bellarine peninsula in Victoria, Australia presented to our hospital with a 2-week history of a non-healing ulcer on her left forearm. The patient had no history of trauma or procedures to the skin. On presentation, the patient had a punch biopsy, which was culture positive for M. abscessus. The isolate was susceptible to clarithromycin and amikacin, had intermediate susceptibility to ciprofloxacin, cefoxitin and linezolid and was resistant to doxycycline, imipenem, cotrimoxazole and moxifloxacin. The tigecycline MIC was 0.25 μg/ml. The patient received a total of 12 weeks of oral clarithromycin 500 mg twice daily, 4 weeks of intravenous amikacin 500 mg daily, 6 weeks of intravenous tigecycline 100 mg over 24 hours via Baxter pump, and 4 weeks of oral clofazimine 100 mg daily. The patient made a good clinical recovery and had her medical therapy ceased after 12 weeks. M. abscessus cutaneous infection in an immunocompetent individual without antecedent trauma or surgery is rare. Our case illustrates the successful treatment of a deep M. abscessus cutaneous ulcer with relatively short duration macrolide-based antibiotic therapy without any surgical intervention.

show abstract

“…We reviewed the literature and found three articles describing long-term administration of tedizolid after linezolid-induced hematologic toxicity. 10,14,15 These articles reported a total of four cases, in one of which tedizolid was given for 58 days and then withdrawn because of the decrease in hemoglobin levels, whereas in the other three cases, no toxicity issues were observed for the 56, 88, and 180 days of tedizolid treatment (the latter case was of a patient with multiple myeloma treated for nocardiosis).…”

Section: Discussionmentioning

confidence: 99%

Long-Term Safety of Tedizolid in a Patient With Spondilodiscitis After Switch From Linezolid Due to Toxicity

Álvarez

Pardo

García

et al. 2018

Infect Dis Clin Pract

View full text Add to dashboard Cite

The patient is a 57-year-old man with liver cirrhosis, Bricker anastomosis after a radical cystoprostatectomy and, a history of bacteremias caused by extended-spectrum β-lactamase-positive Escherichia coli, Enterococcus faecium, and Candida albicans. He presented with persistent low back pain and was diagnosed with vertebral osteomyelitis, for which he received ertapenem-linezolid treatment. However, after 20 days, linezolid had to be discontinued because of myelotoxicity and metabolic acidosis. The patient was switched to tedizolid, which, in combination with ertapenem, was successfully given for 114 days until biopsy showed no growth of gram-positive cocci. We conclude that tedizolid can be an alternative to linezolid in case of toxicity, especially in long-term treatments.

show abstract

Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments

Cited by 15 publications

References 6 publications

Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery

Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery

Medical management of atraumatic Mycobacterium abscessus cutaneous infection: A case report

Long-Term Safety of Tedizolid in a Patient With Spondilodiscitis After Switch From Linezolid Due to Toxicity

Contact Info

Product

Resources

About